Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised the price target on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) to $15 from $14 while maintaining a Buy rating. The firm sees the affordable medicines theme staying attractive in 2026. Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma … Read more